LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Zogenix, Inc. to Contact the Firm

NEW YORK–(BUSINESS WIRE)–Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ:ZGNX) of
the June 11, 2019 deadline to seek the role of lead plaintiff in a
federal securities class action that has been filed against the Company.

If you invested in Zogenix stock or options between February 6, 2019
and April 8, 2019
and would like to discuss your legal rights, click
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292
or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the U.S. District Court for the Northern
District of California on behalf of all those who purchased Zogenix
securities between February 6, 2019 and April 8, 2019 (the “Class
Period”). The case, Lake v. Zogenix, Inc. et al., No.
19-cv-01975 was filed on April 12, 2019, and has been assigned to Judge
Richard Seeborg.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by failing to disclose that: (1) Zogenix’s NDA
for FINTEPLA contained inadequate non-clinical data and an incorrect
version of a clinical dataset; (2) consequently, Zogenix’s NDA for
FINTEPLA was unlikely to gain FDA approval; and (3) as a result, the
Company’s public statements were materially false and misleading at all
relevant times.

On April 8, 2019, Zogenix issued a press release announcing that the
Company had received an RTF letter from the FDA stating that the
Company’s NDA for FINTEPLA was not sufficiently complete to permit a
substantive review.

On this news, Zogenix’s share price fell from $51.85 per share on April
8, 2019 to a closing price of $39.96 on April 9, 2019: a $11.89 or a
22.93% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Zogenix’s conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential


685 Third Avenue, 26th Floor
York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
(877) 247-4292 or (212) 983-9330


Content is the most important part of having quality links to your website. With Area-Info.net, we provide a quality location to share your story and include links to your website to help you grow. If you would like to learn more, visit this page to see how you can use Area-Info.net to rank higher and quicker in search engines. Contact me directly at [email protected] with any questions, or to schedule speaking engagements.

You May Also Like